Adipose tissue plays an important role in tumor progression, because it provides nutrients and adipokines to proliferating cells. Fatty acid binding protein 4 (FABP4) is a key adipokine for fatty acid transport. In metabolic pathologies, plasma levels of FABP4 are increased. However, the role of this circulating protein is unknown. Recent studies have demonstrated that FABP4 might have a role in tumor progression, but the molecular mechanisms involved are still unclear. In this study, we analysed the role of eFABP4 (exogenous FABP4) in breast cancer progression. MCF-7 and MDA-MB-231 breast cancer cells did not express substantial levels of FABP4 protein, but intracellular FABP4 levels increased after eFABP4 incubation. Moreover, eFABP4 enhanced the proliferation of these breast cancer cells but did not have any effect on MCF-7 and MDA-MB-231 cell migration. Additionally, eFABP4 induced the AKT and MAPK signaling cascades in breast cancer cells, and the inhibition of these pathways reduced the eFBAP4-mediated cell proliferation. Interestingly, eFABP4 treatment in MCF-7 cells increased levels of the transcription factor FoxM1 and the fatty acid transport proteins CD36 and FABP5. In summary, we showed that eFABP4 plays a key role in tumor proliferation and activates the expression of fatty acid transport proteins in MCF-7 breast cancer cells.
INTRODUCTION
Breast cancer is the most frequent malignancy in women and the second leading cause of cancerrelated deaths [1] . Epidemiologic studies have indicated that obesity is associated with a higher risk of certain cancers, including postmenopausal breast cancer. This positive association may be partly explained by insulin resistance, hyperinsulinaemia, sustained hyperglycaemia, glucose intolerance, oxidative stress, and inflammation. Emerging research has also begun to focus on the role of circulating adipokines (i.e., adipocyte-secreted factors) in breast cancer [2] [3] [4] . Moreover, patients with metabolic syndrome and diabetes have an increased risk of developing postmenopausal breast cancer [5, 6] .
Fatty acid binding protein 4 (FABP4) is an adipokine that transports fatty acids to various cellular compartments to exert their metabolic functions [7, 8] . FABP4 is implicated in several critical cellular processes, such as the uptake and intracellular storage of fatty acids and the regulation of gene expression, cell proliferation, and differentiation [7] .
FABP4 has gained increasing interest in recent years because we and others identified circulating FABP4 as a metabolic and vascular risk biomarker. FABP4 is released from adipocytes and macrophages and is present in human blood. High blood levels of this protein are associated with some metabolic diseases, such as obesity, metabolic syndrome, type 2 diabetes and atherosclerosis, thus making FABP4 a useful prognostic marker for these pathologies [9] [10] [11] [12] [13] [14] [15] [16] [17] . Moreover, we have described how eFABP4 (exogenous FABP4) is involved in controlling the proliferation and migration of human smooth muscle cells from the coronary artery [18] . While FABP4 was initially described in adipocytes and macrophages, current evidence has demonstrated the expression of this protein in different cell types and in some tumors [19] [20] [21] . FABP4 has increasingly been thought to have important role in tumor progression, but few studies have explored the relationship between FABP4 and breast cancer. FABP4 has been described as a new prognostic factor in bladder cancer, in residual disease of ovarian cancer, and in obese patients with breast cancer [22] [23] [24] . Moreover, FABP4 is overexpressed in glioblastomas and could have a pro-angiogenic role because it is regulated by VEGF and bFGF. [20, 21] .
FABP4 is a mediator of interactions between bone marrow adipocytes and prostate tumor cells [25] . eFABP4 promotes tumor progression in prostate cancer [26] . Finally, FABP4 is a key protein in the migration of ovarian cancer cells. Given the various aforementioned functions of FABP4, this protein is a very good target for the prevention or treatment of some types of cancer [19] .
While much effort in recent years has been focused on uncovering the role of FABP4, the role of eFABP4 in breast cancer is still unknown. The objective of this study was to analyse the role of eFABP4 in breast cancer progression.
RESULTS

eFABP4 is Internalised by Breast Cancer Cells
We demonstrated previously that eFABP4 is internalized in different cell line models [18, 27] . Here, we examined the role of eFABP4 in breast cancer. First, we analysed the expression of FABP4 in MCF-7 and MDA-MB-231 cells. These breast cancer cells did not express FABP4 protein at considerable levels ( Figure 1A ). Next, we assessed whether eFABP4 is internalized by breast cancer cells. We added 100 ng/ml of recombinant eFABP4 to the culture medium, and we detected eFABP4 expression by western blotting ( Figure 1A ; 36.79-fold increase in MCF-7 cells, ÃÃÃÃ P < 0.0001 vs. unstimulated cells; 19.13-fold increase in MDA-MB-231 cells, ÃÃÃ P ¼ 0.0002 vs. unstimulated cells) and immunofluorescence ( Figure 1B ; 100% FABP4 positive cells in MCF-7 and 85.14% FABP4 positive cells in MDA-MB-231 cells, ÃÃÃÃ P < 0.0001 vs. unstimulated cells). These results showed that eFABP4 is internalized in MCF-7 and MDA-MB-231 cells. This internalization could have some impact on breast cancer progression and metabolism; therefore, we decided to study the role of this exogenous protein in cell proliferation, cell migration and the expression of fatty acid transport proteins.
eFABP4 Induces Breast Cancer Cell Proliferation
After demonstrating that eFABP4 is internalized by breast cancer cells, we investigated whether eFABP4 induces breast cancer cell proliferation. A cell proliferation assay was performed by assessing levels of BrdU incorporation. We observed that eFABP4 increased breast cancer cell proliferation in a dose-dependent manner (Figure 2A and B). eFABP4 treatment (20-100 ng/ml) significantly ( Figure 2A ; ÃÃÃÃ P < 0.0001) increased BrdU incorporation in MCF-7 cells compared to in untreated MCF-7 cells, demonstrating the effects of this protein on MCF-7 cell proliferation at 20 ng/ml, 40 ng/ml, and 100 ng/ml of eFABP4 ( Figure 2A; ÃÃ P < 0.005 and ÃÃÃÃ P < 0.0001 vs. unstimulated cells). Moreover, 100 ng/ ml of eFABP4 induced an increase in BrdU incorporation in MDA-MB-231 cells ( Figure 2B ; Ã P < 0.05 vs. unstimulated cells), but lower concentrations of eFABP4 did not have this effect. Thus, eFABP4 induced MCF-7 and MDA-MB-231 cell proliferation.
Next, we analysed the effect of eFABP4 on breast cancer cell migration using a wound-healing assay. However, eFABP4 treatment (20-100 ng/ml) did not have an effect on MCF-7 or MDA-MB-231 cell migration at any of the time points examined time examined (6 h and 24 h) ( Figure 3A and B), suggesting that eFABP4 does not have any effect on breast cancer cell migration under these conditions.
We also determined the effects of eFABP4 on cell cytotoxicity and viability. To assess cell cytotoxicity, we used an LDH detection kit. We did not observe any significant modifications in LDH secretion levels at 24-48 h after the treatment of breast cancer cells with eFABP4 (100 ng/ml) ( Figure S1A ). Therefore, no cytotoxic effects were observed in any of the experiments performed. On the other hand, when we examined the effect of eFABP4 on cell viability, we observed a significant but small increase in the viability of MDA-MB-231 cells at 48 h after eFABP4 treatment (100 ng/ml) ( Figure S1B ; Ã P < 0.05 vs. untreated cells). Thus, eFABP4 had a slight effect on increasing cell viability in MDA-MB-231 cells. However, this difference is probably not biologically relevant.
eFABP4 Induces the AKT and MAPK Pathways in Breast Cancer Cells
The MAPK and AKT pathways play an important role in cancer progression, so we analysed the role of eFABP4 in MAPK and AKT activation. After 5-15 min of eFABP4 treatment (100 ng/ml), we observed an increase in the phosphorylation of the ERK and AKT proteins (Figure 4A and B; 3.09-fold increase in AKT and 4.31-fold increase in MAPK in MCF-7 cells; 2.80-fold increase in AKT and 1.67-fold increase in MAPK in MDA-MB-231 cells; Ã P < 0.05 and ÃÃ P < 0.005 vs. unstimulated cells), which is indicative of the activation of these proteins.
As shown above, eFABP4 induced cell proliferation in breast cancer cells. Therefore, we analysed whether this induction is mediated by the MAPK and AKT pathways. We performed proliferation experiments with eFABP4 in the presence or absence of a PI3 K/AKT (LY-294002, 5 mM) or MAPK (PD98059, 10 mM) inhibitor. eFABP4 was unable to induce cell proliferation in breast cancer cells in the presence of either the PI3 K/AKT or the MAPK inhibitor ( Figure 5A , MCF-7 and Figure 5B , MDA-MB-231; ÃÃÃÃ P < 0.0001 and Ã P < 0.05 vs. untreated cells). Therefore, eFBAP4 mediates cell proliferation through MAPK and AKT pathway activation.
eFABP4 Increases the Expression of FoxM1 in MCF-7 Cells
FoxM1 is a transcription factor that controls key processes in cancer progression, such as cell proliferation [28] ; therefore, we next analysed whether eFABP4 could regulate this transcription factor. After 24 h of treatment with eFABP4 (100 ng/ml), the expression of the FoxM1 protein increased in MCF-7 cells ( Figure 6A ; 4.64-fold increase, Ã P ¼ 0.028 vs. untreated cells). In contrast, the levels of FoxM1 in MDA-MB-231 cells did not change significantly ( Figure 6B ). Thus, eFABP4 induces cell proliferation not only by the activation of the PI3 K/AKT and MAPK/ERK pathways but also by increasing levels of the oncogene FOXM1.
eFABP4 Induces the Expression of FABP5 and CD36 in MCF-7 Cells
Because fatty acid transport proteins have been implicated in cancer progression [29] , we examined whether eFABP4 has any effect on the regulation of other fatty acid transport proteins, such as FABP5 and CD36. To this end, we treated breast cancer cells with 100 ng/ml of eFABP4 for 24 h, and total cell extracts were analysed by western blotting for the expression of FABP5 and CD36. eFABP4 increased FABP5 and CD36 protein levels in MCF-7 cells but not in MDA-MB-231 cells (Figure 6A and B; 1.685-fold increase in FABP5 and 27.03-fold increase in CD36; ÃÃÃÃ P < 0.0001, ÃÃÃ P ¼ 0.0001 and Ã P < 0.05 vs. untreated cells). In addition, MCF-7 and MDA-MB-231 cells were incubated with eFABP4 for 24 h, and immunofluorescence staining was performed with anti-FABP5 and anti-CD36. Immunofluorescence images showed higher levels of FABP5 and CD36 in MCF-7 cells that were incubated with eFABP4 compared to control cells, but no changes were found in MDA-MB-231 cells ( Figure 6C and E, ÃÃÃÃ P < 0.0001 and Ã P < 0.05 vs untreated cells for MCF-7 cells; Figure 6D and E, MDA-MB-231 cells). Therefore, lipid metabolism-related proteins are differentially expressed and regulated in these two breast cancer cell lines.
DISCUSSION
Adipocytes are active and important modulators of the tumor microenvironment by direct contact with neighbouring cells or by secreted adipokines [25] , Thus, the role of some adipokines in cancer has been established [30] , Recent studies have demonstrated that autocrine, endocrine, and paracrine adipokines may contribute to the regulation of breast cancer development and progression [31, 32] . FABP4 is a fatty acid transport protein that has been implicated in some metabolic disorders. Moreover, FABP4 has been implicated in cancer cell growth and metastasis [33, 34] . Despite these data, little is known about the role of FABP4 in breast cancer. In this study, we examined the role of eFABP4 in breast cancer progression.
Previously, we and others have reported increased levels of circulating FABP4 in individuals with some metabolic diseases. Moreover, FABP4 has a direct effect on peripheral tissues and can interact with the plasma membrane by binding to CK1 [27] . These previous results demonstrated that circulating FABP4 is not simply a biomarker; rather, it may have a causal relationship with these diseases due to its interactions with other cell types.
To define the role of eFABP4 in breast cancer progression, we assessed whether eFABP4 is internalized by breast cancer cells. Our results demonstrated that eFABP4 was internalized in MCF-7 and MDA-MB-231 cells (Figure 1A and B;
ÃÃÃÃ P < 0.0001 and P ¼ 0.0002 vs. untreated cells). These results agree with those of others [26] and with our previous data [18, 27] , reinforcing the idea that eFABP4 could have a central role in breast cancer cells. However, FABP4 is not highly expressed in these breast cancer cells. In this sense, adipose tissue could have an active role in breast cancer progression by providing adipokines, such as FABP4, to breast cancer cells.
Next, we analysed the role of eFABP4 in cell proliferation and migration. We found that eFABP4 increased cell proliferation (Figure 2 ) but not cell migration ( Figure 3 ) in MCF-7 and MDA-MB-231 cells. In fact, cell proliferation was affected in a dosedependent manner. BrdU incorporation increased upon the addition of 20 to 100 ng/ml of eFABP4 in MCF-7 cells ( Figure 2A; ÃÃ P < 0.005 and ÃÃÃÃ P < 0.0001 vs. untreated cells) and with 100 ng/ml of eFABP4 in MDA-MB-231 cells ( Figure 2B ; Ã P < 0.05 vs. untreated cells). These concentrations are physiologically relevant given that Hancke et al. [24] described serum FABP4 levels of 41.16 ng/ml in obese women (BMI > 25) and 24.95 ng/ml in non-obese women (BMI < 24.9). Importantly, there is a significant difference between the results obtained with 20 and 100 ng/ml of eFABP4 in MCF-7 cells ( Figure 2A; ÃÃ P < 0.005 20 ng/ml vs. 100 ng/ml), pointing to the importance of not only the presence of the protein but the concentration as well.
Cell growth can be promoted by the activation of a signaling network that induces pathways that are mediated by phosphoinositide 3-kinase (PI3K-AKT) and extracellular signaling kinase (MAPK-ERK). For this reason, we analysed whether eFABP4 can activate these two pathways. eFABP4 induced AKT and MAPK pathway activation, as defined by the detection of phospho-AKT (Ser 473 ) and phospho-p42/p44 (Thr 202 / Tyr 204 ) ( Figure 4 ; Ã P < 0.05 and ÃÃ P < 0.005 vs. unstimulated control). Therefore, eFABP4 induces cell proliferation by activating the phosphoinositide 3-kinase (PI3K-AKT) and extracellular signaling kinase (MAPK-ERK) pathways.
It is notable that the increase in proliferation upon eFABP4 introduction is approximately 20-50%. This eFABP4-mediated enhancement in proliferation rates is likely to depend on the steady-state proliferation rates of the breast cancer cells before treatment. As a fair number of these pretreated cells would be proliferating and expressing substantially high levels of P-AKT, P-MAPK, and FOXM1 after 24 h of 0.1% FCS starvation, the additional proliferative potential that is inducible by eFABP4 may be limited. This idea is supported by the observation that treatment with PI3 K/AKT and MAPK inhibitors can reduce the proliferation eFABP4-treated cells to levels much lower than those exhibited by the cells prior to eFABP4 treatment ( Figure 5; ÃÃÃÃ P < 0.0001, Figure 2 . Effect of eFABP4 on the proliferation of breast cancer cells. Effect of eFABP4 (20-100 ng/ml) on the proliferation of MCF-7 ( Figure 2A ) and MDA-MB-231 ( Figure 2B ) cells was assessed by BrdU incorporation. The results are expressed as the mean AE SEM of three independent experiments run in quintuplicate.
ÃÃÃÃ P < 0.0001, ÃÃ P < 0.005, and Ã P < 0.05 versus untreated cells.
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Molecular Carcinogenesis Ã P < 0.05). In addition, other growth factors, such as long-chain fatty acids, will also be needed to complement eFABP4 and thereby induce proliferation. Moreover, the proliferation effects of eFABP4 will also depend on its stability, rates of uptake and metabolism. The FOXM1 transcription factor has a central function in cell cycle progression and cell proliferation. Moreover, FOXM1 overexpression has been identified in many types of cancers, including breast cancer. In addition, there is a key role for FOXM1 in tumorigenesis, cancer progression and drug resistance [28] . We assessed whether eFABP4 has any role in FOXM1 regulation; treatment with 100 ng/ml of eFABP4 induced FOXM1 expression in MCF-7 cells (Figure 6A and B; Ã P < 0.05) but did not have any effect in MDA-MB-231 cells ( Figure 6A and B) . Thus, eFABP4 can regulate cancer cell proliferation by different mechanisms: the activation of PI3K-AKT and MAPK-ERK pathways and the induction of FOXM1 transcription factor expression in MCF-7 cells.
Several proteins have been identified to facilitate the uptake of fatty acids into cells, and these proteins are deregulated in some cancers, such as breast cancer [29] . Accordingly, we analysed whether eFABP4 is able to induce the expression of other fatty acid transport proteins. We demonstrated that eFABP4 increased the levels of CD36 and FABP5 (Figure 6A and B; western blotting and Figure  6C , D, and E immunofluorescence; ÃÃÃÃ P < 0.0001, ÃÃÃ P ¼ 0.0001, and Ã P < 0.05 vs untreated cells) in MCF-7 cells but not in MDA-MB-231 cells. Balaban et al. [29] reported that CD36 levels were low in breast cancer cells and they describe how the levels of CD36 in MCF7 cells were higher than those in MDA-MB-231 cells. In our experiments, we have observed the same pattern; in the basal state, MDA-MB-231 cells did not express CD36 at appreciable levels, and MCF7 cells exhibited low-level expression of this fatty acid transport protein. However, we observed that in the presence of some exogenous stimuli, such as eFABP4, the levels of endogenous CD36 were increased in MCF7 cells but not in MDA-MB-231 cells. These results are in agreement with several recent publications reporting that some lipid compounds upregulate CD36 levels in some breast cancer cell lines [35] [36] [37] . Breast cancer cells can adapt their lipid metabolism to increase the catabolism of their lipids. This metabolic adaptation may provide benefits for breast cancer cell growth [35] . Moreover, the oncogenic transformation of breast cells by HER2 overexpression may require a reprogramming of lipogenic 
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genes, such as CD36 and FABP4 [36] . Perhaps during the early stages of breast cancer progression, such as cell proliferation, cells could exhibit increased activation of lipid metabolism proteins, such as fatty acid transport proteins. Then, during the later stages of breast cancer progression, such as cell migration, the role of these fatty acid binding proteins could change. As a consequence, under some pathological conditions in which modified crosstalk occurs between adipose tissue and breast cancer cells, the breast cancer cells could take advantage not only of the lipid metabolism products provided by the adipocytes but also of the modifications of lipid metabolism in breast cancer cells, such as the upregulation of fatty acid transport proteins.
In fact, MCF-7 and MDA-MB-231 breast cancer cells exhibit differences in the regulation of lipid metabolism pathways [38] . Therefore, lipid metabolismrelated proteins are differentially expressed and regulated in these two breast cancer cell lines.
The role of FABP4 in some tumors has been described previously, but in this paper, we described a new role for eFABP4 in breast cancer. Adipose tissue has a crucial role in breast cancer development. In fact, some adipokines from this tissue have been implicated in breast cancer progression [2] [3] [4] . Here, we described the role of eFABP4 in breast cancer progression, emphasizing the role of eFABP4 in cell proliferation and regulation of expression of fatty acid transport proteins. FABP4 could have three roles in the control of breast cancer development: (i) FABP4 could induce angiogenesis in breast cancer tissue, as has been shown in glioblastomas [20, 21] ; (ii) FABP4 could be over-expressed in breast cancer tissue [39] , even though other authors have described the opposite expression [40] ; and (iii) eFABP4 from the surrounding adipose tissue could have a central role in cancer progression, as we have described in this paper and as has previously been described for ovarian and prostate cancers [19, 26, 31] . Moreover, the majority of the FABP4 that is in circulation is generated by the stromal compartment; [41] thus, adipose tissue could have a central role in breast cancer progression.
Finally, the cross-talk between adipokines/adipose tissue and breast cancer tissue should be reciprocal. Breast cancer cells could induce fatty acid and adipokine mobilization from adipose tissue. This process could be through the control of FABP4 secretion in adipose tissue by regulating the lipolysis secretory pathway [42] or the calcium-dependent secretion mechanism [43] . Interestingly, increased FABP4 release from adipose tissue has been observed in adipocytes that are exposed to hypoxia [44] . This condition is frequently found in tumor tissue and in the adipose tissue of obese individuals. In summary, we described a novel role for eFABP4 in breast cancer progression. eFABP4 induces breast cancer cell proliferation by activating the PI3K-AKT and MAPK-ERK pathways. Moreover, in MCF-7 cells, eFABP4 induces the expression of the potent oncogene FOXM1 and the fatty acid transport proteins CD36 and FABP5.
Thus, FABP4 might act as a paracrine adipokine and may be one of the key molecules for understanding the mechanisms underlying the obesity-breast cancer progression link and the cross-talk between cacer cells and adipose tissue in non-obese patients.
MATERIALS AND METHODS
Cell Culture and Reagents
Human MCF-7 and MDA-MB-231 breast cancer cells were kindly provided by Professor Eric W. Lam (Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum, 1 mM glutamine, 1 mM penicillin-streptomycin and 1 mM NEAA (Biowest, Nuaill e, France) in a humidified incubator at 378C with 5% CO 2 . Before the initiation of the assays, the cells were changed into DMEM supplemented with 0.1% FBS for 24 h.
MCF-7 and MDA-MB-231 cells were treated with increasing concentrations (20, 40 , and 100 ng/ml) of recombinant FABP4 (eFABP4) (Biovendor, Brno, Czech Republic) for 24 h. To study the activation of proliferation pathways in these cells, the PI3 K inhibitor LY294002 (5 mM) and the MAPK inhibitor PD98059 (10 mM) (Calbiochem-Merck, Darmstadt, Germany) were used.
Western Blotting
MCF-7 and MDA-MB-231 cells were lysed in 2% SDS buffer (2% SDS and 67 mmol/l Tris HCl pH 6.8). Protein concentrations were determined using the Lowry assay. Thirty micrograms of total protein were separated on 10% SDS-PAGE gels and transferred to nitrocellulose membranes using an iBlot 1 Dry Blotting System (Life Technologies, Madrid, Spain). Antibodies against AKT, pAKT (Ser473), p44/p42 MAPK (Erk1/2), p-p44/p42 MAPK (Erk1/2) (Thr202/Tyr204) and GAPDH were obtained from Cell Signalling Technology, Inc. (Beverly, MA). The FOXM1 (C-20) antibody was obtained from Santa Cruz Biotechnology (Dallas, TX). The FABP5 antibody was obtained from (R&D Systems, Inc., Minneapolis, MN). The CD36 antibody was obtained from (Abcam plc, Cambridge, UK). Membranes were incubated with the appropriate HRP-conjugated secondary antibody (Dako, Glostrup, Denmark). The bands were visualized using ECL reagents (GE Healthcare Europe GmbH, Barcelona, Spain) with the ChemiDoc image system and quantified with Image Lab software, version 5.2 (Bio-Rad, Alcobendas, Madrid, Spain). The ratio of target proteins to GAPDH was used to reflect the relative levels of the target proteins.
Immunofluorescence Microscopy
MCF-7 and MDA-MB-231 cells were incubated in chambered slides (Nunc, Roskilde, Denmark) with or without eFABP4 (100 ng/ml) for 24 h, fixed with 4% paraformaldehyde (Sigma-Aldrich, Madrid, Spain) for 
Cell Proliferation Studies
The cell proliferation assay was performed with a colorimetric bromodeoxyuridine (BrdU) enzymelinked immunosorbent assay (ELISA) kit (Roche Diagnostics, Basel, Switzerland), according to the manufacturer's instructions. Briefly, 10,000 cells were seeded into a 96-well microplate and cultured with increasing concentrations of eFABP4 (20-200 ng/ml) and LY294002 (5 mM) or PD98059 (10 mM) for 24 h. The cells were labelled with BrdU labeling reagent overnight. After fixation, the cells were incubated with an anti-BrdU antibody for 90 min. Finally, 100 ml of substrate (tetramethylbenzidine) was added to each well, and the plates were incubated at room temperature for 30 min. The absorbance at 450 nm was measured with an ELISA reader (Synergy H4, Biotek).
In Vitro Wound-Healing Assay MCF-7 and MDA-MB-231 cells were cultured in 12-well plates until they reached confluence. Then, the cells were maintained for 24 h in 0.1% FBS medium. A single scratch wound was created in the centre of the cell monolayer by gently removing the attached cells with a sterile plastic pipette tip. The cells were incubated with eFABP4 (20-200 ng/ml), and images were taken at 0 h and then every 2 h until 24 h of treatment; the images were compared to quantify the migration rate of the cells. The closure of the wound represented 100% migration. The cell images were captured using a microscope (Olympus IX71, Spain) and analysed using imaging software (X cell).
Viability Analysis
MCF-7 and MDA-MB-231 cells were seeded at 7,500 cells/cm 2 in p96 plates. The cells were starved in 0.1% FBS-containing medium for 24 h and treated with eFABP4 (20-200 ng/ml). The CellTiter-Glo 1 Luminescent Cell Viability Assay was performed according the manufacturer's protocol. To determine the number of viable cells in culture, the amount of ATP present was quantitated (Promega Biotech Ib erica, SL., Alcobendas, Madrid).
Cytotoxicity Analysis
MCF-7 and MDA-MB-231 cells were seeded at 10,000 cells/cm 2 in p96 plates. The cells were starved in 0.1% FBS-containing medium for 24 h and treated with eFABP4 (20-200 ng/ml). A cytotoxicity assay was performed by analysing LDH release into the medium using the Cytotoxicity Detection Kit (Roche Diagnostics, Roche Diagnostics, Sant Cugat del VallesBarcelona, Spain).
Statistics
The results represented the means AE SEM of at least three separate experiments. Differences between the means were determined using a t-test (2-tailed) or a one-way analysis of variance (ANOVA), which was followed by a Bonferroni's post-hoc test for multiple comparisons. The differences were considered significant at P < 0.05. GraphPad Prism 6.01 software (GraphPad Software Inc., La Jolla, CA) was used for the statistical analyses.
